This study aims to compare the effectiveness and safety of two medicines, **rilvegostomig** and **pembrolizumab**. These are treatments for a type of lung cancer called **metastatic non-small cell lung cancer (mNSCLC)**. Metastatic means the cancer has spread beyond the lungs. The study is for adults whose cancer cells show a protein called **PD-L1**. **PD-L1** helps some cancers hide from the immune system. The trial is **Phase III**, which means it's quite advanced and involves many people. It's also **double-blind**, meaning neither the doctors nor the participants know who is getting which treatment. This helps ensure fairness and accuracy.

• **Study Length and Visits:** Participants will need to visit the study site regularly, but the exact schedule will be shared by the research team.
• **Risks:** Possible side effects or risks will be explained before participation.
• **Eligibility and Compensation:** Participants must meet specific health criteria, and details on any compensation will be provided by the study coordinators.

Discuss with your doctor if this study fits your needs, and ensure you understand all the details before joining.